Sanofi India receives order for ₹35.6 Lakhs tax, interest, and penalty for FY19
Sanofi India received an order from Gujarat tax authorities for FY19, demanding ₹35.6 Lakhs. This includes ₹10.8 Lakhs tax, ₹14 Lakhs interest, and ₹10.8 Lakhs penalty due to GST compliance issues. The company plans to appeal the decision.
The amount of ₹35.6 Lakhs is significant enough to impact the company's financials, but it is not considered a material impact given the company's overall revenue and profitability. The company's intention to appeal also mitigates some of the immediate impact.
The company has received an order for tax, interest, and penalty, which is a negative financial event. Although they plan to appeal, the initial order is unfavorable.
Sanofi India Limited has received an order from the Assistant Commissioner, Ahmedabad, Gujarat, for the financial year 2018-19. The order determines a total demand of ₹35,62,876, which includes ₹10,80,000 in tax, ₹14,02,876 in interest, and ₹10,80,000 in penalty.
The demand arises from the non-submission of vendor confirmation for tax paid by vendors whose GST registration has been cancelled, and a mismatch in Input Tax Credit (ITC) claims appearing in GSTR-2A.
The company intends to appeal this order before the Higher Tax Authorities. The order was dated 17th December 2025 and received by the company on 19th December 2025.
What to do with a filing like this
Sanofi India Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Sanofi India Limited. Read the original for the full detail.